STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ('Applied DNA' or the 'Company'), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on order for Linea™ DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) for a global manufacturer of in vitro diagnostics (IVD).

纽约州石溪市/ACCESSWIRE/2023年11月28日/基于PCR的DNA技术领导者应用DNA科学公司（纳斯达克股票代码：APDN）（'Applied DNA'或'Company'）今天宣布收到Linea的后续订单™ DNA值高于六位数字。该订单是根据长期供应协议为全球体外诊断（IVD）制造商批量生产Linea DNA（非治疗性）。

Under the terms of the repeat order, deliveries are expected to commence during the fiscal quarter ending March 31, 2024, through the fiscal quarter ending December 31, 2024..

根据重复订单的条款，预计交付将在截至2024年3月31日的财政季度开始，直至截至2024年12月31日的财政季度。。

'We continue to see strong demand for IVD-related applications for Linea DNA. We believe our platform is optimal for the cost-effective and large-scale production of specialized DNA sequences used in IVD applications, and especially those that are too large for conventional oligonucleotide synthesis or require chemical modification.

'我们继续看到对线性DNA的IVD相关应用的强烈需求。我们相信我们的平台对于IVD应用中使用的专门DNA序列的成本效益和大规模生产是最佳的，特别是那些对于常规寡核苷酸合成来说太大或需要化学修饰的DNA序列。

These are potentially high margin, recurring revenues with an opportunity for incremental revenues through new customer acquisition and as existing customers validate and expand Linea DNA use to other assays,' stated Dr. James A. Hayward, president and CEO of Applied DNA..

应用DNA总裁兼首席执行官James A.Hayward博士说，这些潜在的高利润率，经常性收入有机会通过新客户收购获得增加收入，并且随着现有客户验证并将线性DNA用于其他分析。。

About Linea™ DNA

关于线路™ 脱氧核糖核酸

Linea™ DNA is an enzymatically produced linear DNA manufactured by the Company's proprietary, large-scale polymerase chain reaction ('PCR') based manufacturing platform, the Linea™ DNA platform. Linea DNA serves as an alternative to plasmid-based DNA that has been utilized in the manufacture of biotherapeutics for the past 40 years.

Linea™ DNA是一种酶法生产的线性DNA，由该公司专有的、大规模的基于聚合酶链式反应的生产平台Linea生产™ DNA平台。Linea DNA可作为基于质粒的DNA的替代品，过去40年来已用于制造生物治疗药物。

Linea DNA is relevant to the next generation of nucleic acid-based therapies and diagnostics, including mRNA production, DNA vaccines, cell and gene therapies, as well as numerous veterinary medicine applications..

Linea DNA与下一代基于核酸的疗法和诊断相关，包括mRNA产生，DNA疫苗，细胞和基因疗法，以及许多兽医应用。。

About Applied DNA Sciences

关于应用DNA科学

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ('DNA'). Using the polymerase chain reaction ('PCR') to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc.

Applied DNA Sciences是一家生物技术公司，开发生产和检测脱氧核糖核酸（'DNA'）的技术。使用聚合酶链式反应（'PCR'）来生产和检测DNA，我们在三个主要商业市场开展业务：（i）用于生产基于核酸的治疗剂的合成DNA的酶促生产，以及通过我们最近收购的Spindle Biotech，Inc。

('Spindle'), the development and sale of a proprietary RNA polymerase ('RNAP') for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services..

（'Spindle'），开发和销售用于生产mRNA治疗剂的专有RNA聚合酶（'RNAP'）；（ii）在分子诊断和基因检测服务中检测DNA和RNA；（iii）制造和检测用于工业供应链安全服务的DNA。。

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

访问adnas.com了解更多信息。在Twitter和LinkedIn上关注我们。加入我们的邮件列表。

The Company's common stock is listed on NASDAQ under ticker symbol 'APDN,' and its publicly traded warrants are listed on OTC under ticker symbol 'APPDW.'

该公司的普通股在纳斯达克以勾号“APDN”上市，其公开交易的认股权证在场外以勾号“APPDW”上市

Forward-Looking Statements

前瞻性声明

The statements made by Applied DNA in this press release may be 'forward-looking' in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA.

应用DNA在本新闻稿中所作的陈述本质上可以是1933年“证券法”第27A条，1934年“证券交易法”第21E条和“私人证券诉讼改革法”1995年。前瞻性陈述描述了应用DNA的未来计划，预测，策略和期望，并且基于假设并涉及许多风险和不确定性，其中许多超出了应用DNA的控制范围。

Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics or diagnostic products and services, the unknown amount of revenues and profits that will result from the Linea DNA™ and/or Linea™ IVT platforms, limited market acceptance for its supply chain security products and services, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT or Linea DNA platforms approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 14, 2022, as amended, its 10-Q filed on February 9, 2023, May 11, 2023, and August 10, 2023, and other reports it files with the SEC, which are available at www.sec.gov.

由于其净损失历史，有限的财政资源，对其生物治疗药物或诊断产品和服务的未知未来需求，线性DNA产生的未知收入和利润，实际结果可能与预计结果有很大差异™ 和/或直线™ IVT平台，其供应链安全产品和服务的市场接受程度有限，从未使用PCR生产的DNA技术和/或批准用于治疗用途的Linea IVT或Linea DNA平台的商业药品，以及各种其他因素在Applied DNA的SEC报告和文件中不时详述，包括其于2022年12月14日提交的经修订的表格10-K年度报告，2023年2月9日，2023年5月11日和2023年8月10日提交的10-Q年度报告，以及其他报告，可在www.SEC.gov上查阅。

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law..

除非法律另有要求，否则Applied DNA没有义务公开更新任何前瞻性声明，以反映本协议签署之日以后的新信息，事件或情况，或反映意外事件的发生。。

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

投资者关系联系人：Sanjay M.Rush，917-733-5573，sanjay.hurry@adnas.com

Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com

计划联系人：Brian Viscount，631-240-8877，brian.viscount@adnas.com

Web: www.adnas.com

网址：www.adnas.com

Twitter: @APDN

推特：@APDN

###

###

SOURCE: Applied DNA Sciences, Inc.

资料来源：应用DNA科学公司。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/810720/applied-dna-announces-receipt-of-lineatm-dna-follow-on-order-for-cancer-diagnostic-application

https://www.accesswire.com/810720/applied-dna-announces-receipt-of-lineatm-dna-follow-on-order-for-cancer-diagnostic-application